Clinical Trial Update: Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial comparing ABI-007 (Abraxane) to Taxotere in first-line metastatic breast cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ABI-007 (Abraxane, nab-paclitaxel) (nab-paclitaxel)
• Taxotere (docetaxel)

Snippet

Sponsor: Celgene | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-07-02